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1. Introduction
Adult  T-cell  leukemia/lymphoma (ATL) was first  described in 1977 as a distinct  clinico‐
pathological  entity with a suspected viral  etiology.  Subsequently,  a  RNA retrovirus,  hu‐
man T-cell leukemia /lymphotropic virus type 1 (HTLV-1) was isolated as a carcinogenic
pathogens [1].
HTLV-1 infects approximately 15 to 20 million people worldwide, with endemic areas in Japan,
the Caribbean, and Africa.
After prolonged latency periods, approximately 3 to 5% of HTLV-1 infected individuals will
develop either ATL or other disorders such as HTLV-1-associated myelopathy/tropical spastic
paraparesis (HAM/TSP).
2. Transmission and spread
The three major routes of HTLV-1 transmission are, 1)mother-to-child infections via breast
milk, 2)sexual intercourse, and 3)blood transfusions. HTLV-1 infection early in life, presuma‐
bly from breast feeding, is crucial in the development of ATL [2].
3. Initial infection
HTLV-1 infects  CD4+ and CD8+ T lymphocytes  and can also  efficiently  infect  dendritic
cells [3].
© 2013 Kobayashi and Iwasaki; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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The ubiquitous glucose transporter 1 and the neuropilin 1 were identified as members of the
HTLV-I receptor complex [4,5].
Moreover, surface heparan sulfate proteoglycans were shown to be required for efficient virus
entry [6]. Clonal expansion of HTLV-infected cells mostly relies on the promotion of cycling
CD4+ T cells [7].
4. Infected cell types
CD4+ lymphocytes and to a lesser extent CD8+ T cells are considered to be as the main targets
of HTLV-1. Plasmacytoid dendritic cells (pDC) were also infected by HTLV-1 in patients. In
fact, all types of dendritic cells have been shown to be easily infected by HTLV-1 in vitro and
efficiently transmit HTLV-1 to T cells in free viral transmission [8].
The proviral load was higher in isolated pDCs than in T cells. pDCs was found to be stimulated
type I interferon α and β which interacted with their cognate receptors on virus infected cells
and, through IFN-inducible genes, interfered with viral replication. pDCs from ATL patients
were known to be impaired in their production of IFN-α. These observations supported a role
for pDC in viral persistence and disease progression [9].
CD4+ T cells can be divided into two major categories: effector T cells and regulatory T
cells(Treg). Effector T cells induce the activation of immune responses by secreting proinflam‐
matory cytokines, whereas Treg which express the transcription factor FoxP3, suppress
immune responses by both cell-contact dependent and –independent mechanisms. A propor‐
tion of HTLV-1 infected CD4+ T cells express FoxP3. It showed that HTLV-1 infection induces
the phenotype of FoxP3+CD4+ T cells [7].
5. HTLV-1 virus
5.1. HTLV-1-encoded proteins
The HTLV-1 genome contains typical structural and enzymatic genes (gag, pro, pol and env)
flanked by two long terminal repeats (LTRs). (Fig. 1). The long terminal repeats (LTR) are
subdivided into three regions (i.e., U3, R and U5) that contain the cis-acting elements essential
for viral gene expression: transcription factor-binding sites, transcription start and termination
sites, polyadenylation and splicing sites. A region called pX, which is located between the env
gene and the 3′-LTR, contains at least four partially overlapping reading frames (ORFs)
encoding accessory proteins (p12I, p13II, p30II), the post-transcriptional regulator Rex (ORF
III) and the Tax transactivator (ORF IV). In addition, HBZ is encoded from the 3′ LTR in the
complementary strand of the genome. Among all these regulatory proteins, Tax and HBZ
proteins appear to have particularly important roles in viral persistence and pathogenesis [10].
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Figure 1. HTLV-1 proviral gene
5.2. Tax (transcriptional transactivator) (p40)
Tax is a major factor that mediated the following: 1)viral persistence and disease development.
2) oncogenic potential, 3)cell-signalling pathways, 4)interferes with checkpoint control and
inhibition of DNA repair, and 5) modulation of the miRNAs environment [11].
Among the cellular pathways activated by Tax, CREB/ATF, NF-κB and AP1 are thought to
have predominant roles in T-cell proliferation and transformation.
Tax -mediated NF-κB activation stimulates expression of cytokines and their receptors such
as interleukin 2 (IL2)/IL2 receptor (IL2R), IL9, IL13 and IL15/IL15R as well as members of the
tumour necrosis factor receptor family.
A major activity of Tax in signaling pathways is the stimulation of G1/S transition. Tax
increases the levels of type D cyclin levels in G1 and activates cyclin-dependent kinases (i.e.,
CDK4 and CDK6) through direct binding, leading to Rb hyperphosphorylation, subsequent
release of E2F transcription factor and accelerated transition from G1 to S. Tax also directly
interacts with and promotes the degradation of Rb. Furthermore, Tax modulates expression
of CDK inhibitors such as p18INK4c, p19INK4d, p21WAF1 and p27KIP1 and inactivates
p15INK4b and p16INK4a through direct binding, thereby restraining their inhibitory activity
toward CDKs.
Tax  stimulate  viral  production  and  infection,  however,  the  Tax  expression  is  transient
and rapidly turned off  (Fig 2).  Cells  that  failed to shut off  the Tax are rejected by host
immune response, such as cytotoxic T lymphocytes (CTL) and only the cells with latent
viral  expression  should  survive.  Repeating  these  cycles  for  long  periods,  results  in  the
persistence of infected individuals in a virus carrier state, however Tax-incuced mutaions
accumulated in infected cells.
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Three mechanisms have been described for inactivating Tax expression in ATL cells have been
described: 1) genetic changes (nonsense mutation, deletion, and insertion) in the tax gene, 2)
deletion of the 5' long terminal repeat (LTR) that contains the viral promoter, and 3) DNA
methylation of the 5 ' LTR leading to promoter inactivation.
Tax-mediated mutation would be a critical event in ATL that triggers the clonal selection of
infected T cells as malignant leukemia cells [12].
′
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Figure 2. Probable mechanism of pathogenesis in ATL progression
5.3. Other proteins; Rex, p12, p13 and p30
Rex (p27) is an RNA-binding post-transcriptional regulator that binds to its cis-acting target
sequence, the Rex response element (RRE), located at the 3′-end of sense viral mRNAs.
HTLV-1 contains both regulatory and accessory genes in four pX open reading frames. pX.
ORF-II encodes two proteins, p13 and p30.
Proviral clones of HTLV-1 with pX ORF-II mutations diminish the ability of the virus to
maintain viral loads in vivo. p30 is acting as a repressor of many genes including Tax, in part
by blocking tax/rex RNA nuclear export.
p30 expression results in activation of the G2-M cell cycle checkpoint, events that would
promote early viral spread and T-cell survival. [13,14].
The role of four open reading frames (ORFs), located between env and the 3' long terminal
repeat of HTLV-1. By differential splicing, ORF II encodes two proteins, p13(II) and p30(II).
p13(II) localizes to mitochondria and may alter the configuration of the tubular network of this
cellular organelle.
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Mutations in pX ORF II diminish the ability of HTLV-1 to maintain high viral loads in vivo
and suggest an important function for p13(II) and p30(II) in viral pathogenesis. [15].
The repression in Tax expression is essential to protect infected cells from immune response
and to maintain the virus. However, recent studies suggested that a loss of Tax expression also
prevents Tax-induced mitotic aberrations that are detrimental to cell proliferation and
therefore, to stabilize the karyotype of infected T cells [16].
5.4. HBZ
A recently identified HBZ factor. HTLV-1 bZIP, acts as a negative regulator of Tax-mediated
viral transactivation by heterodimerising with CREB, CREB2, and p300/CBP. HBZ RNA
expression leads to the upregulation of E2F1 target genes and stimulation of T lymphocyte
proliferation [17].
The HBZ protein was first reported to function as a transcription factor that repressed viral
expression by competing with Tax-mediated LTR activation.
As previously, Tax is highly immunogenic and its expression induces an immune response
that generates CTL primarily directed against this oncoprotein. To escape this CTL-mediated
lysis and to maintain viral persistence, HTLV-I infected cells frequently reduce Tax expression
by several mechanisms.
HBZ was expected to be responsible for inducing and maintaining the tumor state even after
Tax was shut off, which was supported by evidence that HBZ transcription was correlated
with the proviral load [18-20].
Similar to Tax, HBZ interacts with proteasome subunits and may promote the delivery of
cellular factors (such as c-Jun) to the proteasome even in the absence of ubiquitination.
6. Tumor marker
Similar to serum LDH reflecting disease bulk/activity, the soluble form of interleukin-2
receptor α-chain is elevated. [21].
The mean sIL-2R levels of the smoldering, chronic, acute, and lymphoma subtypes of ATL
were 1680 U/ml, 6680 U/ml, 45,940 U/ml, and 34,620 U/ml, respectively (P < 0.01). The sIL-2R
levels of each subtype at the time of diagnosis were more correlated with tumor burden,
malignant behavior, and prognosis than LDH levels. In the low, moderate, and high sIL-2R
subgroups, the median survival time and percent survival probability at 2 years was 30.2
months (46.0%), 16.5 months (25.0%), and 7.7 months (15.3%), respectively.
These serum markers are useful to detect acute transformation of indolent ATL as well as to
detect early relapse of ATL after therapy.
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7. Immunophenotype
In most patients, ATL cells exhibit the phenotype of mature CD4+ T cells and express CD2,
CD5, CD25, CD45RO, CD29, T-cell receptor αβ, and HLA-DR. Most ATL cells are CD52, CCR4
positive, but occasionally, patients are negative. Immunophenotypic analysis of CD3, CD4,
CD7, CD8, and CD25 is the minimum requirement for an ATL diagnosis.
8. Cytogenetics
Karyotypic abnormalities revealed by conventional cytogenetics or comparative genomic
hybridization are more common and complex in the acute and lymphoma types compared
with the chronic type, with aneuploidy and several hot spots such as 14q and 3p. More sensitive
array-comparative genomic hybridization revealed that the lymphoma type had significantly
more frequent gains at 1q, 2p, 4q, 7p, and 7q and more losses of 10p, 13q, 16q, and 18p, whereas
the acute type showed a gain of 3/3p [22.23].
9. Molecular biology of host genome
Mutation or deletion of tumor suppressor genes, such as p53 or p15INK4B/p16INK4A, is
observed in approximately half of ATL patients and is associated with clinical subtypes and
prognosis.These new molecular markers may help guide therapeutic decisions. [24].
To  predict  to  respond  to  antiviral  therapy  with  AZT and  IFN-alpha,  the  expression  of
proto-oncogene c-Rel  and interferon regulatory factor-4  (IRF-4)  was examined.  Resistant
tumors  exhibited  c-Rel  (6  of  10;  60%)  more  often  than  did  sensitive  variants  (1  of  9;
11%). This finding was independent of the disease form. Elevated expression of the puta‐
tive c-Rel target,  IRF-4,  was observed in 10 (91%) of 11 nonresponders and in all  tested
patients with c-Rel+ tumors and occurred in the absence of the HTLV-1 oncoprotein Tax.
In  contrast,  tumors  in  complete  responders  did  not  express  c-Rel  or  IRF-4.  The  expres‐
sion of nuclear c-Rel  and IRF-4 occurs in the absence of  Tax in ATLL and is  associated
with antiviral resistance. [25].
10. Molecular biology of HTLV-1
Monoclonal integration of HTLV-1 proviral DNA is observed in all cases of ATL. Integration
of defective HTLV-1 into ATL cells is observed in approximately one-third of ATL patients
and is associated with clinical subtypes and prognosis. It is recommended to perform molec‐
ular analysis of HTLV-1 integration when possible. Either Southern blotting or polymerase
chain reaction for HTLV-1 can be used to identify the presence of viral integration, although
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the latter can also be used for quantitative purposes. Clinically, ATL is diagnosed on the basis
of seropositivity for HTLV-1 and histologically and/or cytologically proven peripheral T-cell
malignancy. [26].
11. Pathogenesis
Tax is a multifunctional protein that affects various cellular machinery and signaling pathways
to mediate cellular transformation and viral replication.
The necessity of NF-κB, a transcription factor, in Tax-mediated transformation was confirmed
in which a single point mutation in the Tax that disrupts to activate the NFκB pathway also
eliminates the viral ability to transform [27].
11.1. Tax-independent NF-κB activation
However, Tax expression is lost in approximately 60% of all ATLs during the late stages of
leukemogenesis stages. Notably, NF-κB pathways remain still strongly activated in HTLV-1-
infected Tax-negative cells, suggesting the existence of Tax-independent mechanism. Report‐
edly, Tax-independent NF-κB activation occurs in Tax-positive cells. Several mechanisms are
speculated in Tax-independent NF-κB activation, such as IKKB activation and the NF-κB
member c-Rel [28-31].
HTLV-1 infection induces expression of many NF-κB stimulators and signaling molecules such
as TNF, CD40, CD30, and Bcl-3. TNF is the prototypic stimuli of NF-κB activation, while CD40
and CD30 are potent activators of NF-κB pathways. Bcl-3 binds to p50 or p52 homodimers and
transforms them from transcription repressors into activators [32-35].
11.2. Persistent NF-κB activation by HTLV-1
Tax binds to and increases the stability and activity of NF-κB and/or prevents NF-κB from
binding to its inhibitors, resulting in a prolonged and elevated activation of NF-κB. NF-κB
activation is aberrantly persistent, irrespective of whether it is Tax-dependent or -independent.
A main reason for this abnormal activation is the co-existence and cross-activation of different
NF-κB and NF-κB-related signaling pathways. [36-40].
In addition to NF-κB, Tax induces many other signaling pathways such as the phosphatidy‐
linositol 3-kinase (PI3K)/AKT and DNA damage signaling pathways, leading to reciprocal
enhancement of these pro-oncogenic pathways with NF-κB. Most of the mechanisms activate
Tax-independent and -dependent NF-κB pathway. [41.42].
11.3. Differences between tax-dependent and tax-independent NF-κB activation by HTLV-1
NF-κB signaling pathways are  persistently  activated in  HTLV-1-infected cells  regardless
of  Tax  expression.  Tax-dependent  and -independent  NF-κB pathways  also  involve  acti‐
vation  of  common  and  distinct  NF-κB  members.  NF-κB  members  activated  in  Tax-ex‐
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pressing  T  cells  are  predominantly  RelA,  c-Rel,  p50  and  p52,  and  those  in  Tax-
negative  T  cells  are  mainly  RelA  and  p50.  Consistent  with  the  role  of  positive
feedback  mechanisms  in  persistent  NF-κB  activation,  expression  of  c-Rel  and  p100/p52
expression  is  induced  in  Tax-expressing  cells,  whereas  p105/p50  mRNA  expression  is
enhanced in ATL cells  [43,44].
11.4. NFκB and apoptosis
Lymphoma cell lines including ATL cells, that were constitutively activated NFκB are resistant
to various inducers of apoptosis including irradiation, etoposide, and combinations of
cycloheximide and TNF or TRAIL, and resist the activation of both the intrinsic and extrinsic
apoptotic pathways [45].
Although mutations that delete or inactivate p53 are common in ATLL, Tax can bypass p53-
dependent cell-cycle checkpoints.
A  Tax  transgenic  mouse  model  was  analyzed  for  study  the  contribution  of  p53  inacti‐
vation  to  Tax-mediated  tumorigenesis.  The  mice  develop  primary,  peripheral  tumors
consisting  of  large  granular  lymphocytic  (LGL)  cells,  which  infiltrate  the  lymph nodes,
bone  marrow,  spleen,  liver,  and  lungs.  Tax-induced  tumors  exhibited  functional  inacti‐
vation  of  the  p53  apoptotic  pathway;  such  tumors  were  resistant  to  an  apoptosis-in‐
ducing stimulus.  Experiments  with  mating  Tax  transgenic  mice  with  p53-deficient  mice
demonstrated  minimal  tumor  acceleration,  but  significantly  accelerated  disease  progres‐
sion  and  death  in  mice  heterozygous  for  p53.  The  studies  suggest  that  inactivation  of
p53  by  Tax,  whether  by  mutation  or  another  mechanism,  is  not  critical  for  initial  tu‐
mor formation,  but  contributes  to  late-stage tumor progression [46,47]..
11.5. Telomerase
Telomerase is compsed of hTR, a 451 nucleotide stretch of RNA, which serves as a template
for the RNA-dependent DNA polymerase, telomerase(hTERT).
Telomere length is also regulated by several positive and negative regulators These proteins
can them prevent telomerase extension by blocking access of the reverse transcriptase to the
now “closed”ends of telomeric DNA.
AZT is a thymidine analog, that has been shown to inhibit cancer growth and telomerase
activity. Long-term treatment of HTLV-1 infected cells with AZT inhibits telomerase activity
induces telomere attrition and promotes cellular senescence, in absence of apoptosis, due to
the reactivation of tumor suppressor p53 transcriptional activities
Analysis of ATLL patients was done to examine the relationship between the responsive‐
ness for antiviral therapy and p53 mutation. Those patients with a mutated p53 did not re‐
spond to AZT treatment, demonstrating that AZT treatment causes telomere attrition
leading to the reactivation of a functional p53. [48.49].
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12. Response criteria
Complete remission (CR) is defined as a normalization of the complete blood count associated
with a disappearance of all measurable tumors. The effect has to last for at least 1 month.
However, patients with a persistence of < 5% of atypical lymphocytes are considered in CR
because this situation may be observed in healthy carriers of HTLV-I. Patients who achieve
CR with persistence of > 5% of atypical lymphocytes are considered in very good partial
response. Partial response is defined as a decrease of > 50% in the number of leukemic cells
and in the size of all measurable tumors. The effect has to last for at least 1 month. No response
is defined as < 50% decrease in the number of leukemic cells or in the size of any measurable
tumor or as disease progression. Patients who meet the CR or partial-response criteria but with
the effect lasting < 1 month are classified as nonresponders.
13. Prognostic factors
Major prognostic indicators for ATL were analyzed in 854 patients; advanced performance
status (PS), high LDH level, age ≥ 40 years, more than three involved lesions, and hypercalce‐
mia are prognostic factors that have been identified by multivariate analysis. These factors
were used to construct a risk model.5
For the chronic type of ATL, high LDH, high blood urea nitrogen, and low albumin levels have
been identified as poor prognostic factors by multivariate analysis. Univariate analysis has
revealed that neutrophilia,p16 deletion, and chromosomal deletion detected by comparative
genomic hybridization are associated with poor prognosis in chronic ATL.
In contrast, chronic lymphoid leukemia (CLL)–like morphology of ATL cells was associated
with longer transformation-free survival of chronic ATL. Primary cutaneous tumoral type,
although generally included among smoldering ATL, was a poor prognostic factor by
univariate analyses [50].
The prognosis of acute- and lymphoma-type adult T-cell leukemia/lymphoma (ATL) is poor,
but there is marked diversity in survival outcomes.
Data from 807 patients newly diagnosed with acute- and lymphoma-type ATL were evaluated
and developed a PI using a multivariable fractional polynomial model. The Ann Arbor stage
(I and II v III and IV), performance status (0 to 1 v 2 to 4), and three variables (age, serum
albumin, and soluble interleukin-2 receptor [sIL-2R]) were identified as independent prog‐
nostic factors. Using these variables, a prognostic model was devised to identify different levels
of risk. In the validation sample, MSTs were 3.6, 7.3, and 16.2 months for patients at high,
intermediate, and low risk, respectively (P <.001).
A total of 854 ATL patients were analyzed for prognostic factors. Patients were 466 males and
388 females with a mean age of 57.1. A Cox proportional hazards model analysis revealed that
five factors, advanced performance status, high lactic dehydrogenase value, age of 40 years or
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more, increased number of total involved lesions and hypercalcemia, were associated with
shortened survival(P<0.01).
These factors were used to construct a model to identify patients at three different risks for
shortened survival. A group of 178 patients (21.8%) with a hazard ratio of less than 0.5 were
classified into the low risk (LR) group, 492 (60.4%) with hazard ratio of less than or equal to
0.5 and less than 2.5 into standard high risk (SHR) group, and 145 (17.8%) with hazard ratio
of 2.5 or more extremely high risk (EHR) group. MST, and projected 2- and 4-year survival
rates were 37 months, 66.3% and 41.2% for LR, 8 months 20.6%, and 4.5% for SHR, and 2.4
months, 5.6% and 0% for EHR, respectively.
14. Classification
The following diagnostic criteria are proposed to classify four clinical subtypes of ATL(Table
I); 1) Smouldering type, 2) Chronic type, 3) Lymphoma type, and 4) Acute type.
1. Smouldering type, 5% or more abnormal lymphocytes of T-cell nature in PB, normal
lymphocyte level (less than 4 x 10(9)/l), no hypercalcaemia (corrected calcium level less
than 2.74 mmol/l), lactate LDH value of up to 1.5 x the normal upper limit, no lympha‐
denopathy, no involvement of liver, spleen, central nervous system (CNS), bone and
gastrointestinal tract, and neither ascites nor pleural effusion. Skin and pulmonary
lesion(s) may be present. In case of less than 5% abnormal T-lymphocytes in PB, at least
one of histologically-proven skin and pulmonary lesions should be present.
2. Chronic type, absolute lymphocytosis (4 x 10(9)/l or more) with T-lymphocytosis more
than 3.5 x 10(9)/l, LDH value up to twice the normal upper limit, no hypercalcaemia, no
involvement of CNS, bone and gastrointestinal tract, and neither ascites nor pleural
effusion. Lymphadenopathy and involvement of liver, spleen, skin, and lung may be
present, and 5% or more abnormal T-lymphocytes are seen in PB in most cases.
3. Lymphoma type, no lymphocytosis, 1% or less abnormal T-lymphocytes, and histologi‐
cally-proven lymphadenopathy with or without extranodal lesions.
4. Acute type, remaining ATL patients who have usually leukaemic manifestation and
tumour lesions, but are not classified as any of the three other types.
A total of 818 ATL patients with a mean age of 57 years, newly diagnosed from 1983 to 1987,
were analysed by this criteria. 253 were still alive with a median follow-up time of 13.3 months
from diagnosis, while 565 were dead with a median survival time (MST) of 5.4 months. MST
was 6.2 months for acute type, 10.2 months for lymphoma type, 24.3 months for chronic type,
and not yet reached for smouldering type. 2- and 4-year survival rates were 16.7% and 5.0%
for acute type, 21.3% and 5.7% for lymphoma type, 52.4% and 26.9% for chronic type, 77.7%
and 62.8% for smouldering type, respectively. Distinct clinical features and laboratory findings
of each clinical subtype are described [51].
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Smouldering Chronic Lymphoma Acute
Lymphocyte count Less than 4 4 or more less than 4 more than 4
(10 9 lympho/liter)
% of atypical lympho 5 or more 5 or more 1 or less more than 5
LDH 1.5x NUL 2x NUL
Ca less than 2.74 less than 2.74 more than 2.74
Lyphoadenopathy No No Yes -
Mean survival time(Mo) 24.3 10.2 6.2
2 year survival (%) 77.7 52.4 21.3 16.7
4 year survival (%) 62.8 26.9 5.7 5
NUL Normal upper limit
Table 1. Classification of subtypes
15. Treatment options
The treatment of ATL usually depends on the subtype. Patients with aggressive forms have a
very poor prognosis due to intrinsic chemoresistance, a large tumor burden, and frequent
infectious complications because of immune deficiency.
In multiple Japanese trials for aggressive ATL, data clearly demonstrated that combinations
of chemotherapy did not have significant effect on long-term survival. Indolent ATL pa‐
tients(chronic or smoldering) have a better prognosis. However, recent data from Japanese
showed poor long-term results when these patients were managed with a watchful-waiting
policy until progression or with chemotherapy [52].
15.1. Conventional chemotherapy
The clinical trials in Japan(protocols LSG1-VEPA and LSG2) demonstrated that first-genera‐
tion chemotherapy, such as CHOP type, ie, cyclophosphamide, hydroxydaunorubicin,
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oncovin (vincristine), and prednisone has little impact in ATL, especially in the acute type.
Only a 16% to 36% patients achieved CR.
New-generation agents such as deoxycoformycine, a nucleoside analog, irinotecan hydro‐
chloride (CPT-11: a topoisomerase I inhibitor), and MST-16(a topoisomerase II inhibitor), have
also been tested in pilot phase II studies of refractory or relapsed ATL patients, however the
results have been uniformly disappointing.
A phase III study in Japan demonstrated that the LSG15 regimen consisting of VCAP (vin‐
cristine, cyclophosphamide, doxorubicin, prednisolone), AMP (doxorubicin, ranimustine,
prednisolone), and VECP (vindesine, etoposide, carboplatin, prednisolone) is superior to
biweekly CHOP for newly diagnosed acute, lymphoma, or unfavorable chronic ATL. The CR
rate and 3-year overall survival(OS) were greater as 40% vs 25%, 24% vs 13%, respectively,
however,the median 13 months survival was disappointing [53].
The poor prognosis of ATL after chemotherapy is probably the consequence of several factors.
The cellular immune deficiency observed at the early stages may lead to a high frequency of
opportunistic infections. Overexpression of the multidrug resistant gene and p53 gene
mutations is a feature of ATL cells and results in intrinsic resistance to chemotherapy.
15.2. Monoclonal antibodies
15.2.1. CC Chemokine Receptor 4 (CCR4)
CC chemokine receptor 4 (CCR4) is a chemokine receptor expressed on T-helper type 2 and
regulatory T cells. Because CCR4 is expressed on most ATL cells, KW-0761, a humanized anti-
CCR4 monoclonal antibody, which markedly enhances antibody-dependent cellular cytotox‐
icity, was evaluated in the treatment of patients with relapsed ATL. [54].
A multicenter phase II study of KW-0761 for patients with relapsed, aggressive CCR4-positive
ATL. Patients received intravenous infusions of KW-0761 once per week for 8 weeks at a dose
of 1.0 mg/kg. Of 28 patients enrolled in this study, responses were noted in 13 of 26 evaluable
patients, including CR in 8, with an overall response rate of 50%. The median progression-free
time and overall survival were 5.2 and 13.7 months, respectively. The most common adverse
events were infusion reactions (89%) and skin rashes (63%), which were manageable and
reversible in all the cases.
Because monoclonal antibodies were tried as single agents, trials are needed to define in
combination therapies with chemotherapy in the lymphoma form or with antiretroviral
therapy in the acute form. Following on a phase III study(JCOG9801(Japan Clinical Oncology
Group 9801) for untreated aggressive ATL promote to conduct a randomized trial of VCAP-
AMP-VECP chemotherapy with or without KW-0761 for untreated ATL.
15.2.2. CD52
CD52 is also the candidate target. A monoclonal antibody against CD52(Alemtuzumab) has
demonstrated good results: however, the results are scanty and limited to case reports. with
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or without nucleoside analogs such as pentostatin may be promising. However, the associated
immunosuppression is a concern in patients with viral-mediated disease. [55-57].
15.3. HSC transplantation
The several retrospective studies have confirmed that allogeneic SCT(allo SCT) with the use
of either myeloablative conditioning or reduced-intensity conditioning conditioning as a
promising treatment option for ATL.
The number of ATL patients eligible for allo SCT is quite limited because of the older age at
presentation (>60 years), poor performance status, the severe immunosuppression, and the
low CR rate, in particular in the acute form.
Although selection criteria for patients and sources of stem cells remain to be resolved, allo-
SCT may be considered as a treatment option for patients with aggressive ATL.
For treating aggressive ATL, LSG15 is the standard chemotherapy, however, its efficacy of
LSG15 is transient. Improved outcome after allo-SCT, despite a high incidence of graft-versus-
host disease, has been reported.
To evaluate whether allo-SCT is more effective than LSG15 for aggressive ATL, an up front
phase II clinical trial is now being planned. [1].
15.3.1. Donor selection
Total 386 patients with ATL who underwent allo-SCT using different graft sources were
evaluated [58].
154 received human leukocyte antigen (HLA)-matched related marrow or peripheral blood;
43 received HLA-mismatched related marrow or peripheral blood; 99 received unrelated
marrow; and 90 received single unit unrelated cord blood. After a median follow-up of 41
months (range, 1.5-102), the 3-year OS for the entire cohort was 33% (95% confidence interval,
28%-38%). Multivariable analysis showed that 4 recipient factors were significantly associated
with lower survival rates: older age (> 50 years), male sex, status other than CR, and the use
of unrelated cord blood compared with use of HLA-matched related grafts. Treatment-related
mortality rate was higher among patients given cord blood transplants; disease-associated
mortality was higher among those given transplants not in remission. Among transplants,
donor HTLV-I seropositivity adversely affected disease-associated mortality.
15.3.2. Conditioning regimen
A retrospective study of allo SCT for ATL were conducted in Japan for the effects of the
preconditioning regimen [59].
The median OS and 3-year OS of bone marrow or peripheral blood transplantation recipients
(n=586) were 9.9 months (7.4-13.2 months) and 36% (32-41%), respectively.
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The values for recipients of myeloablative conditioning (MAC: n = 280) and reduced-intensity
conditioning (RIC: n = 306) were 9.5 months (6.7-18.0 months) and 39% (33-45%) and 10.0
months (7.2-14.0 months) and 34% (29-40%), respectively.
Multivariate analysis showed that 5 variables significantly contributed to poorer OS; older age,
male gender, not in CR, poor performance status, and transplantation from unrelated donors.
Although no significant difference in OS between MAC and RIC was observed. Regarding
mortality, RIC was significantly associated with ATL-related mortality compared with MAC.
15.3.3. Graft-Versus-ATL(GVL) effect
The  effects  of  acute  and  chronic  GVHD on  overall  survival,  disease-associated  mortali‐
ty,  and  treatment-related  mortality  among  294  ATL  patients  who  received  allo  HCT
were analyzed [60].
The occurrence of GVHD demonstrated that the development of grade 1-2 acute GVHD
(aGVHD) was significantly associated with higher overall survival (P = 0.018) compared with
the absence of aGVHD. Occurrence of either grade 1-2 or grade 3-4 aGVHD was associated
with lower disease-associated mortality compared with the absence of aGVHD, whereas grade
3-4 aGVHD was associated with a higher risk for treatment-related mortality (P < 0.001). The
development of extensive chronic GVHD (cGVHD) was associated with higher treatment-
related mortality (P = 0.006) compared with the absence of cGVHD. These results indicate that
the development of mild-to-moderate aGVHD attribute a lower risk of disease progression
and a beneficial effect on the survival of ATL patients with allografts.
Clinical studies have suggested that allo SCT improves the clinical course of ATL with a graft-
versus-ATL effect. It is speculated that donor-derived HTLV-1 Tax-specific CD8(+) cytotoxic
T cells (CTLs) contribute to the graft-versus-ATL effect after HSCT.
The frequencies, differentiation, functions and clonal dynamics of Tax-specific CTLs in
peripheral blood (PB) and bone marrow (BM) from an ATL patient were analyzed after HSCT
[61]. Donor-derived Tax-specific CTLs effectively suppressed HTLV-1 replication in both PB
and BM at least during chronic graft-versus-host disease after HSCT.
Tax-specific CTLs persistently existed as less-differentiated CD45RA(-)CCR7(-) effector
memory CTLs based on predominant phenotypes of CD27(+), CD28(+/-) and CD57(+/-). Two
predominant CTL clones persistently existed and maintained strong cytotoxic activities
against HTLV-1 in both PB and BM over three years after HSCT.
To study the GVL effects after allo-HSCT, 21 ATL patients(18 acute, 2 lymphoma and 1 chronic)
were examined [62]. allo-HSCT, seven patients were in CR, one was in PR, five had stable
disease(SD) and eight had progressive disease(PD). The disease after allo-HSCT was CR in 14,
PR in 3, SD in one and PD in 3 patients. Among 15 patients who survived longer than 100 days,
ATL relapsed in 10 patients. After the discontinuing of immunosuppressant therapy in these
10 patients, 8 manifested GVHD; ATL was ameliorated to CR in 6 patients. Donor lymphocytes
were infused into 2 patients who did not show GVHD; 1 obtained CR. In 5 patients with skin
relapse alone, 4 patients achieved CR following the discontinuation of the immunosuppres‐
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sants. From these results, Gv-ATL effects played an important role in the outcome of allo-HSCT
for ATL. [63].
15.4. Antiviral therapy
15.4.1. Zidovudine (AZT) and Interferon(INF)
Zidovudine (AZT) and interferon(INF) are known to be as antiviral agents.
Phase II studies with the combination of AZT and IFN treatment showed a high response rate.
For acute ATL, first-line antiviral therapy alone resulted in a significant survival advantage
(5-year overall survival [OS] of 28%) compared with first-line chemotherapy with or without
maintenance antiviral therapy (5-year OS of 10%). Achieving CR with antiviral therapy
resulted in a 5-year survival rate of 82%.
A study of worldwide meta-analysis on 254 ATL survival treated in the United States, the
United Kingdom, Martinique, and France (116 acute ATL, 18 chronic ATL, 11 smoldering ATL,
and 100 ATL lymphoma) was performed. Five-year OS rates were 46% for 75 patients who
received first-line antiviral therapy, 20% for 77 patients who received first-line chemotherapy,
and 12% for 55 patients who received first-line chemotherapy followed by antiviral therapy.
Patients with acute, chronic, and smoldering ATL significantly benefited from first-line
antiviral therapy, whereas in ATL lymphoma, first-line antiviral therapy resulted in a signif‐
icant survival disadvantage (median and 5-year OS of 7 months and 0%, respectively)
compared with first-line chemotherapy with or without maintenance antiviral therapy
(median and 5-year OS of 16 months and 18%, respectively). Finally, a multivariate analysis
confirmed that first-line antiviral therapy significantly improves overall survival of ATL
patients (hazard ratio 0.47; 95% confidence interval 0.27-0.83; P =.021). [64,65].
Virus  expression  has  been  reported  to  be  limited  or  absent  when  ATLL  is  diagnosed,
and  this  has  suggested  that  secondary  genetic  or  epigenetic  changes  are  important  in
disease pathogenesis.
Nineteen  patients  were  prospectively  enrolled  in  a  phase  II  clinical  trial  of  infusional
chemotherapy with etoposide,  doxorubicin,  and vincristine,  daily  prednisone,  and bolus
cyclophosphamide  (EPOCH)  given  for  two  to  six  cycles  until  maximal  clinical  re‐
sponse,  and  followed  by  antiviral  therapy  with  daily  zidovudine,  lamivudine,  and  al‐
pha interferon-2a for  up to one year  [66].
Seven patients were on study for less than one month due to progressive disease or chemo‐
therapy toxicity. Eleven patients achieved an objective response with median duration of
response of thirteen months, and two complete remissions. Viral reactivation(median 190-fold)
was observed during EPOCH chemotherapy.
Alternative therapies are sorely needed in this disease that simultaneously prevent virus
expression.
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15.4.2. Arsenic trioxide
Arsenic trioxide synergizes with IFN to induce cell-cycle arrest and apoptosis in HTLV-I–
infected and freshly isolated leukemia cells from ATL patients.
The arsenic/IFN combination kills ATL cells through rapid reversal of the constitutive
activation of NF-κB and delayed shut down of cell cycle-regulated genes secondary to Tax
degradation by the proteasome that was concomitant with cell death induction [67]. It was
speculated that that leukemia initiating activity(LIC) is dependent on continuous NF-κB
expression. [68]. Other phase II study, the efficacy and safety of the combination of arsenic,
IFN, and AZT in 10 newly diagnosed chronic patients was evaluated [69]. 100% response rate
was observed, including 7 CR, 2 PR but with > 5% circulating atypical lymphocytes, and 1PR.
Side effects were moderate and mostly hematologic.
The addition of arsenic to AZT/IFN, through elimination of LIC activity, may result in long-
term disease eradication and potential cure. Treatment of arsenic/IFN/AZT combination was
a suboptimal 5-days-per-week treatment, 3 of 6 patients remained in continuous complete
remission for 7-18 months after discontinuation of maintenance therapy, whereas 5 patients
with chronic ATL previously treated with IFN/AZT alone all relapsed, on average before 5
months. Similarly, in an ongoing trial of ATL lymphoma patients, ie, maintenance therapy
with arsenic/IFN after complete remission with chemotherapy, resulted in all assessable
patients remaining in complete remission for 23-44 months, a distinctly uncommon finding in
these diseases. These observations suggest that in ATL patients arsenic/IFN efficiently targets
ATL LIC activity and may be useful as a consolidation therapy.
The results  of  another  phase II  trial  in  which arsenic  was added to  the  combination of
AZT and IFN in  newly diagnosed chronic  ATL were  reported.  All  10  patients  enrolled
responded,  including seven patients  who achieved CR, two patients  who achieved very
good PR,  and one patient  achieved PR.  Side effects  were moderate  and no relapse was
noted at the time of reporting.
These encouraging results suggest that the triple combination of arsenic, AZT and IFN is a
promising even for the first line therapy of ATL.
15.5. Targeting NFκB in ATLL patients
In ATLL cells the NFκB pathway remains activated even after Tax expression is repressed.
Thus NFκB remains a therapeutic target even when Tax is not expressed.
To determine if NFκB blockade is tolerated in these patients, and whether or not it improves
response rates and overall survival, multicenter trial combines infusional chemotherapy
(EPOCH) with bortezomib. This trial includes treatment with integrase inhibitor raltegravir,
which was found to inhibit HTLV-1 integration. The addition of an antiviral agent to this ATLL
treatment regimen is based clinical trial in which chemotherapy was found to markedly
enhance virus expression in a subset of patients.
Bortezomib is another non-specific inhibitor of the NFκB pathway that is capable of inhibiting
proliferation of tumors cells [72]. Bay11-7082, an IKK inhibitor, inhibits the NFκB pathway in
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ATLL cells and sensitizes HTLV-1 infected cells lines as well as primary ATLL cells to apoptosis
[73,74]. Over the past years several additional studies have therapeutically targeted the NFκB
pathway in order to kill ATLL cells
Oridonin, NIK-333, curcumin, fucoidan, and histone-deacetylase inhibitors have all been
reported to induce apoptosis in ATLL cells by repressing the NFκB pathway. The field now
awaits successful clinical trials in vivo [75,76].
15.6. Watch-and-wait policy for indolent ATL
Patients with smoldering or chronic ATL subtypes have a better prognosis than those with
aggressive variants of ATL. Therefore, these 2 ATL subtypes were considered indolent and
were usually managed with a watchful-waiting policy until disease progression. However, the
reported median survival of chronic and smoldering types was only 18 months and 58 months,
respectively, and the OS rates were < 20% at 5 years in both types. From Japanese study with
longer follow-up period, that indolent ATL had a poor prognosis: patients with smoldering
ATL had an estimated 15-year survival rate of 12.7% with a median survival of 2.9 years,
whereas patients with chronic ATL had an estimated 15-year survival rate of 14.7% with a
median survival of 5.3 years. Importantly, patients who received chemotherapy had a
significantly lower survival compared with patients treated on a watch-and-wait policy.
From 1974 to 2003, newly diagnosed indolent ATL in 90 patients (65 chronic type and 25
smoldering type) was analyzed. The median survival time was 4.1 years;  The estimated
5-,  10-,  and  15-year  survival  rates  were  47.2%,  25.4%,  and  14.1%,  respectively,  with  no
plateau in the survival  curve.  Kaplan-Meier  analyses showed that  advanced PS,  neutro‐
philia, high concentration of lactate dehydrogenase, more than 3 extranodal lesions, more
than 4  total  involved lesions,  and receiving  chemotherapy were  unfavorable  prognostic
factors  for  survival.  Multivariate  Cox analysis  showed that  advanced PS  was  a  border‐
line  significant  independent  factor  in  poor  survival  (P  =.06).  The  prognosis  of  indolent
ATL in this study was poorer than expected.
15.7. Telomerase inhibitors
AZT is a thymidine analog that has been shown to inhibit cancer growth and telomerase
activity. HTLV-I infected cells undergo senescence during long-term AZT treatment, du to the
reactivation of tumor suppressor p53 transcriptional activities. This effect is dependent upon
telomere shortening. In vivo patient samples of AZT-treated ATLL patients show decreases in
telomerase activity and telomere lengths [48].
16. Treatment strategy
16.1. Acute ATL
As summarized in Fig. 3, in Japan, at present, LSG15 is the standard chemotherapy for the
treatment of aggressive ATL, but the efficacy of LSG15 in most patients is transient.
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Figure 3. Treatment proposal
To evaluate whether allo-SCT is more effective than the standard chemotherapy (LSG15) for
aggressive ATL, clinical trial are needed.
In United States, an antiviral therapy such as AZT+IFN is recommended [1].
16.2. Chronic and smoldering ATL
Although patients with chronic and smoldering ATL have a better prognosis compared with
patients with acute ATL and ATL lymphoma, long-term survival is dismal when these patients
are managed with a watchful-waiting policy until their disease progresses. Moreover, patients
who received chemotherapy alone had even a poorer outcome.
It is one proposal that patients with chronic and smoldering ATL should be treated with
antiviral therapy. In the worldwide meta-analysis on ATL survival, patients with chronic/
smoldering ATL who received first-line antiviral therapy only had an excellent survival (100%
OS beyond 5 years). The recommended starting dose is AZT 900 mg/d (in 3 divided doses) and
IFN-α (5-6 million IU/m2/d). Usually, after 1 month, AZT dose can be titrated down to 600 mg/
d in 2 divided doses, and the IFN dose can be reduced to 3-5 million IU/d or alternatively 1.5
μg/kg of pegylated IFN weekly. The addition of other antiretroviral agents, such as 3TC
(lamivudine) or zalcitabine, has been tested by several centers. However, no clinical evidence
of added benefit was demonstrated. On the basis of the preclinical data, clinical trials are testing
the effect of adding arsenic to the AZT/IFN combination as a consolidation therapy with the
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aim of then stopping therapy and achieving cure by potential elimination of leukemia-
initiating cells.
16.3. Lymphoma
In Japan, LSG protocol is generally tried. When treated with this LSG15 protocol, ATL
lymphoma patients achieved a better CR rate (66.7%) than acute type (19.6%) or chronic type
(40.0%) patients.
First-line antiviral therapy is less effective than first-line chemotherapy in ATL lymphoma.
Probably, the combination of chemotherapy and AZT/IFN is recommended as front-line
therapy in ATL lymphoma based on the reactivation of HTLV-1 virues.
Based on encouraging results from Japan, allo SCT is recommended for young patients with
ATL lymphoma and sutable donor.
17. Supportive therapy in ATL
Infectious events are often fatal in ATL patients. Sulfamethoxazole-trimethoprim and anti‐
fungal agents were recommended for the prophylaxis of Pneumocystis jiroveci pneumonia and
fungal infections, respectively, in the JCOG trials. Although cytomegalovirus infection
commonly occurs in ATL patients, ganciclovir is not routinely recommended for prophylaxis.
In addition, in patients not receiving chemotherapy, antifungal prophylaxis may not be critical.
18. Prevention
In 1980, investigation of mother-to-child transmission (MTCT) for explaining the infection of
HTLV-1. Epidemiological data revealed the MTCT rate at ∼20%. Cell-mediated transmission
of HTLV-1 without prenatal infection suggested a possibility of milk-borne transmission. A
prefecture-wide intervention study to refrain from breast-feeding by carrier fmothers, the ATL
Prevention Program Nagasaki revealed a marked reduction of HTLV-1 MTCT by complete
bottle-feeding from 20.3% to 2.5%, and a significantly higher risk of short-term breast-feeding
(<6 months) than bottle-feeding (7.4% vs. 2.5%, P < 0.001) [77].
19. Conclusion
Further investigation on the ATL pathogenesis is crucial for the prevention and treatment of
this refractory leukemia/lymphoma. Clinical trials to assess additional targeted therapies such
as NF-kB-targeted therapy or monoclonal antibodies are mandatory after achieving CR.
Allogeneic BMT with the use of conventional or non-myeloablative conditioning should be
considered for suitable patients.
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